Want to see OKUR full AI Analyst Report?
OKUR Stock Chart & Stats
$3.80
-$0.07(-1.70%)
At close: 4:00 PM EDT
$3.80
-$0.07(-1.70%)
Day’s Range― - ―
52-Week Range$2.01 - $5.38
Previous Close$4.05
Volume82.67K
Average Volume (3M)356.77K
Market Cap
$95.57M
Enterprise Value$51.94M
Total Cash (Recent Filing)$176.39M
Total Debt (Recent Filing)$926.00K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 05, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding40,496,307
10 Day Avg. Volume371,463
30 Day Avg. Volume356,773
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-255.88
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$15.00Price Target Upside294.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.83
Revenue Forecast (FY)$500.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improved EquityVery low debt limits fixed financial obligations and reduces leverage risk, while the stronger equity base provides greater capacity to support development activities. This balance-sheet profile gives OnKure more flexibility than a similarly unprofitable biotech with substantial borrowings.
Precision Oncology FocusA focus on precision oncology gives OnKure a clearly defined development strategy centered on genetically selected patient populations. If its candidates demonstrate clinical value, this targeted approach can support focused trials and differentiated positioning within oncology markets.
Losses Closely Track Cash ConsumptionFree cash flow being broadly aligned with reported net loss indicates that current cash consumption is not being materially worsened by unusually large non-cash accounting effects. That improves the transparency of the financial profile, even though the absolute burn remains high.
Bears Say
No Revenue And Widening LossesThe absence of revenue leaves OnKure dependent on future clinical and commercial execution to create an economic return. Meanwhile, widening losses show that spending is increasing without an offsetting revenue base, making profitability an unresolved medium-term challenge.
Persistent Cash BurnConsistently negative operating and free cash flow means the business is consuming capital rather than funding development internally. Continued annual burn increases reliance on external financing, which can constrain strategic flexibility and create ongoing funding or dilution pressure.
Negative Returns On EquityDeeply negative return on equity shows that the current capital base is not yet generating economic returns and is being consumed by operating losses. Until pipeline progress produces revenue or reduces spending needs, shareholder capital remains exposed to weak productivity.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $2.01 and its highest was $5.38 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $95.57M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Aug 04, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $0.225.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 40,496,307 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went up 1.463%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OnKure Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (294.74% Upside)
$15.00 (294.74% Upside)
Blogger Sentiment
Bullish
OKUR Sentiment 75%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.33%
12-Months-Change
Fundamentals
Return on Equity
-49.02%
Trailing 12-Months
Asset Growth
108.38%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OnKure Therapeutics
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
OKUR Stock 12 Month Forecast
Average Price Target
$15.00
▲(294.74% Upside)
Technical Analysis
Ownership Overview
1.73% Insiders
1.69% Mutual Funds
66.92% Other Institutional Investors
22.81% Public Companies and
Individual Investors